1. Home
  2. CVV vs INAB Comparison

CVV vs INAB Comparison

Compare CVV & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVV
  • INAB
  • Stock Information
  • Founded
  • CVV 1982
  • INAB 2016
  • Country
  • CVV United States
  • INAB United States
  • Employees
  • CVV N/A
  • INAB N/A
  • Industry
  • CVV Industrial Machinery/Components
  • INAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CVV Technology
  • INAB Health Care
  • Exchange
  • CVV Nasdaq
  • INAB Nasdaq
  • Market Cap
  • CVV N/A
  • INAB 18.8M
  • IPO Year
  • CVV N/A
  • INAB 2021
  • Fundamental
  • Price
  • CVV $3.11
  • INAB $0.19
  • Analyst Decision
  • CVV
  • INAB Strong Buy
  • Analyst Count
  • CVV 0
  • INAB 2
  • Target Price
  • CVV N/A
  • INAB $3.60
  • AVG Volume (30 Days)
  • CVV 17.2K
  • INAB 726.1K
  • Earning Date
  • CVV 05-12-2025
  • INAB 05-08-2025
  • Dividend Yield
  • CVV N/A
  • INAB N/A
  • EPS Growth
  • CVV N/A
  • INAB N/A
  • EPS
  • CVV N/A
  • INAB N/A
  • Revenue
  • CVV $26,876,000.00
  • INAB N/A
  • Revenue This Year
  • CVV N/A
  • INAB N/A
  • Revenue Next Year
  • CVV N/A
  • INAB N/A
  • P/E Ratio
  • CVV N/A
  • INAB N/A
  • Revenue Growth
  • CVV 11.48
  • INAB N/A
  • 52 Week Low
  • CVV $2.53
  • INAB $0.13
  • 52 Week High
  • CVV $5.25
  • INAB $1.74
  • Technical
  • Relative Strength Index (RSI)
  • CVV 54.18
  • INAB 52.85
  • Support Level
  • CVV $2.91
  • INAB $0.15
  • Resistance Level
  • CVV $3.15
  • INAB $0.19
  • Average True Range (ATR)
  • CVV 0.16
  • INAB 0.01
  • MACD
  • CVV 0.02
  • INAB 0.01
  • Stochastic Oscillator
  • CVV 86.57
  • INAB 92.30

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: